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ABSTRACT
Systems biology approaches have become indispensable tools in biomedical and basic research. These data
integrating bioinformatic methods gained prominence after high-throughput technologies became available to
investigate complex cellular processes, such as transcriptional regulation and protein–protein interactions, on a
scale that had not been studied before. Immunology is one of the medical fields that systems biology impacted
profoundly due to the plasticity of cell types involved and the accessibility of a wide range of experimental
models. In this review, we will focus on peroxisome proliferator-activated receptor c in macrophages and
dendritic cells to highlight the crucial importance of systems biology approaches in establishing novel cellular
functions for long-known signalling pathways.5
Keywords Genome-wide studies6 , immune cells, peroxisome proliferator-activated receptor gamma, systems
biology.
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Introduction
Our body is protected against intruders by multiple layers of
defence, each part of a highly ordered, hierarchical and inte-
grated immune system. Decades of research have led to the
identification of several key molecular components that define
the activity and communication of immune cells; however, our
understanding is still far from complete.
Importantly, traditional research strategies lacking high-
throughput technologies ignored the complexity of biological
systems, screening gene functions on individual targets rather
than focusing on biomolecular networks. Introduction of novel
systems biology approaches opened the way to investigate the
consequences of manipulation of a gene on the entire molecular
network and has revolutionized the way we think about bio-
logical systems and their complexity.
In this review, we will summarize the recently available
peroxisome proliferator-activated receptor gamma (PPARc)-
related ‘omics’ data in the context of macrophages and den-
dritic cells to demonstrate how a single protein can play such a
diverse role in multiple biological processes. We will describe
how genomewide studies from the recent years redefined the
function of the receptor in these cell types. Moreover, we will
demonstrate that re-analysis of existing genomewide studies
can provide further insights into the biological role of a factor
and identify novel cellular signalling pathways.
Systems biology approaches in immunology
Systems biology is the study of a complex entity using a
holistic approach; which enables the prediction of the sys-
tem’s behaviour through the complex relationships among its
components [1]. Such prediction of a system’s behaviour can,
and should be, later validated experimentally. It is clear that a
biological signal is not generated by a particular molecule
alone, but instead by the complex interaction of several factors
[2]. A main driving force behind holistic approaches has been
the development of novel high-throughput methods, such as
microarray, RNA-seq, proteomics, ChIP-seq, RNAi screens
and 3D imaging. These techniques are now indispensable in
biological and medical research. Analysis of data generated
through these methods requires multidisciplinary research
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teams, which include experts from medicine to mathematics
[3].
In the context of the immune system, a complex system of
cells and signalling molecules, the use of mathematical models
and bioinformatics approaches holds great potential in the
identification of novel therapeutic targets [4–6]. Comparing the
transcriptome and proteome of immune cells isolated from
different stages of disease development and progression could
have a significant clinical relevance [3].
Gardy et al. [1] summarized the system biology workflows
available for immunology research, which includes the analysis
of transcriptome, gene expression networks, proteomics, miR-
NAs, genetic polymorphisms as well as network inference and
modelling. Visualization of the high-throughput output infor-
mation is also crucial for understanding and interpreting data.
Advances in this segment can be already seen in the literature
[7]. Using a wide variety of software, published data can be re-
analysed and gene lists or networks can be generated as a
starting point for further experimental research [8–10].
This approach can also be used for studies aiming to identify
drugs that may have potential indications in immunology
(drug repurposing). Data obtained from large data sets can be
utilized to generate networks that associate drugs to genes and
diseases [11]. As an example, PPARc agonists have been pre-
dicted, based on omics data, to have a therapeutic effect in
colorectal cancer [12]. This effect has been confirmed in vivo
experiments [13].
Genomewide studies of transcription factor binding sites
have been performed in a variety of immune cells, including
macrophages and dendritic cells. These approaches pinpoint
the fact that lineage-determining transcription factors take part
in defining the transcriptomic response of the cell upon stim-
ulation [14].
General characteristics of PPARc
PPARc is a ligand-activated transcription factor that directly
binds to specific DNA sequences and can respond to various
ligands [15,16]. Many putative endogenous PPARc ligands
have been identified, most of them derived from unsaturated
fatty acids hydroxyeicosatetraenoic acids and hydroxyoc-
tadecadienoic acids (HODEs), such as 9- and 13-HODE [17,18].
PPARc appears to be a sensor of a group of oxidized lipids, too.
Selective synthetic ligands of PPARc, called thiazolidinediones
are also available, some of them being used in the treatment of
diabetes [19].
PPARc is expressed primarily in adipose tissue and kidney
and is essential for adipogenesis [20–22]. However, PPARc
expression is not limited to metabolic tissues, as it is also
expressed in various cells of the immune system such as macro-
phages, dendritic cells, eosinophils, T cells, and B cells [23–26].
PPARc forms a permissive heterodimer with RXR, another
member of the nuclear receptor superfamily. The PPARc/RXR
heterodimer can recognize specific sequences (PPAR response
element) in the DNA and can initiate transcription of a group of
target genes.
Despite the large amount of data available regarding the role
of PPARc in various model systems, it is safe to say that novel
‘omics’ methodologies allow us a more systematic characteri-
zation and detailed investigation of PPARc function in different
cell types. Transcriptomic data that are already available
helped us to identify PPARc-regulated target genes in different
immune cell types. Cistromic data are also available for PPARc
and RXR and suggest a striking cell type-dependent binding
pattern of PPARc/RXR heterodimer (Fig. 1) [27]. In the fol-
lowing sections, we attempt to systematically summarize our
recent knowledge of PPARc-mediated macrophage and den-
dritic cell functions, including those novel insights that we
could obtain with the application of ‘omics’ technologies.
PPARc in macrophages
Macrophages are a highly heterogeneous population of
immune cells residing throughout the body that participate in
pathogen clearance, inflammatory response and tissue regen-
eration among others. PPARc in macrophages is involved in
lipid metabolism but also in regulation of immune functions.
As mentioned above, PPARs bind various fatty acids and fatty
acid by-products, regulating aspects of lipid metabolism, dif-
ferentiation and cellular growth by transcriptional control of
several downstream genes [28]. The receptor has well-docu-
mented accessory roles in the differentiation of the monocytes
to macrophages in both mouse and human [29,30].
Macrophages, after the exposure of certain cytokines, can be
driven to classical or alternative activation. Although this is a
fairly simplistic view of macrophage polarization, it serves well
to the development of system level concepts, which obviously
would need to be validated for in vivo relevant cell types as
well.
Classical macrophage activation (resulting in the so-called
M1 macrophages) is driven by certain primary stimuli, such as
IFNc and as a second signal, bacterial LPS or cytokine TNF-a,
leading to an inflammatory phenotype secreting TNFa, IL-12,
IL-1, IL-6 and NO [31,32]. As a result, M1 macrophages acquire
phenotypic changes making them capable of fighting a bacterial
infection [33]. On the other hand, alternative activation of
macrophages, mediated by IL-4, leads to an anti-inflammatory
phenotype (M2 macrophages), participating primarily in tissue
remodelling and regenerative processes. M2 macrophages have
decreased levels of inflammatory cytokines and produce large
amount of anti-inflammatory molecules including IL-10 and
TGF-b [34]. PPARc has been implicated in influencing the
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phenotype of both macrophage subsets. Its natural and syn-
thetic ligands inhibit the expression of a wide range of
inflammatory molecules, alleviating the inflammatory response
of M1-like macrophages [35–39]. Furthermore, PPARc agonists
inhibit the transcription of monocyte chemoattractant protein-1
and its receptor CC chemokine receptor 2 (CCR2), affecting the
recruitment of macrophages to inflammatory sites [40–43].
The proposed molecular mechanism, by which PPARc can
repress pro-inflammatory cytokines, is called transrepression.
Corepressor complexes Ncor/HDAC3/TBL are bound to the
promoter of inflammatory genes (i.e. iNOS); this association is
disrupted in response to inflammatory stimuli (e.g. LPS). In
macrophages treated with PPARc agonists, however, the
repressor complexes remain in association with the promoter
even in the presence of LPS. This model proposes the ligand-
dependent SUMOylation of PPARc preventing the ubiquitina-
tion-/proteasome-mediated degradation of the corepressor
complexes [44]. Nevertheless, this model is poorly understood
and does not explain how PPARc can exert two different
actions in the same cell type; in other words, how PPARc
induces the dissociation of the corepressor complexes from the
targeted promoters in order to lead to gene induction and on
the other hand, bind to promoters that are involved in tran-
srepression [45]. Interestingly, Chawla et al. [46] showed that
thiazolodinediones were able to inhibit INFc and IL-6 secretion
both in wild-type and PPARc-deficient macrophages, indicat-
ing that transrepression by PPARc ligands has a receptor
independent component, as well. However, the mechanistic
details of this aspect of transrepression still need to be eluci-
dated. In addition, it has been shown that certain nonthiazo-
lidinedione PPARc agonists do not have anti-inflammatory
effects in macrophages, suggesting that transrepression might
be dependent on the structure and chemical nature of the
ligand [47].
Aiming to elucidate the role of PPARc in the M2 macrophage
subset as well, Szanto et al. [48] performed a comparative
transcriptome analysis in human and mouse macrophages and
demonstrated that pro-inflammatory molecules inhibit,
whereas the treatment with IL-4 increases the expression of
PPARc and its previously known target genes. It was also
shown, using global gene expression analysis in PPARc-defi-
cient mice, which the alternative macrophage activation could
(a)
(b)
Figure 1 17Cell type specificity of peroxisome proliferator-activated receptor gamma (PPARc) transcriptional activity. (a)
Reductionism point of view of PPARc molecular genetics in macrophages (left) and adipocytes (right) on genes Atp6v0d2 and
Adipoq. (b) IGV Browser snapshot showing genes Atp6v0d2 and Adipoq with PPARg, RXR ChIP-seq and RNA-seq data in
macrophages and adipocytes (data obtained from Lefterova et al. 2010, Daniel et al. 2014, Nielsen et al. 2008 and I. Cuaranta-
Monroy unpublished data) [27,87,88]. 7
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be achieved in the absence of PPARc. Furthermore, the gene
expression of alternative activation markers such as Ym1, Arg1
or Fizz1 was not affected upon rosiglitazone treatment. How-
ever, the authors could show in a genomewide analysis that IL-
4, through STAT6, augments PPARc activity by increasing the
magnitude of transcriptional responses orchestrated by the
receptor both in macrophages and in dendritic cells [48].
Analogous to this approach, Scotton et al. [49], Syed et al. (50)
and Czimmerer et al. (51), distinguished IL-4-specific target
genes in human macrophages with the aim to identify alter-
native macrophage activation markers. Applying microarray
technology: CD1b/c/e, TLR1 and C-type lectin superfamily
member 6, IL-1RI, IL-1RII, IL-1Ra, CCL17, CCL22, CCL23,
CCL26, WNT5A, CD180, SLA, MS4A4A among others could be
identified as novel markers. In silico analysis of the macrophage
transcriptome in the presence of IL-4 showed that the cytokine
not only regulates immunological processes but also is poten-
tially implicated in cellular metabolism, cell proliferation and
apoptosis. Transcriptome-based prediction of pathway-specific
transcription factors suggested the importance of PPARc and
nuclear factor erythroid derived 2-like 2 (NFE2L2) in alterna-
tive macrophage activation, among others [49–51]. In addition,
IL-4 induces the expression of 15-lipoxygenase, autotaxin and
monoamine oxidase, enzymes capable of producing ligands for
PPARc [51,52].
As part of an effort to translate findings obtained primarily
using mice to human macrophages, genomewide analysis of
regulator regions occupied by PPARc in murine macrophages
and the human macrophage-like cell line THP-1 was performed
[53]. Interestingly, this study revealed that human and murine
PPARc binding sites are only 5% shared between the two
species; however, 30% of PPARc downstream genes appear to
be conserved through evolution. As part of this analysis, 4302
PPARc/RXR binding sites were found in THP-1 cells. Within
these enriched sequences, up to 60% were co-occupied with the
well-established myeloid lineage specific transcription factor
PU.1 [54], similar to the murine macrophage data. This led to
the proposed model where PU.1 assists PPARc functional
binding both in murine and human macrophages, possibly
through facilitating the remodelling of the chromatin structure.
PPARc expressed by various tissue-specific macrophages has
also been shown to play important roles in the pathophysiology
of diseases ranging from autoimmune disorders to atheroscle-
rosis. An in silico analysis predicted macrophages as a potential
therapeutic target in inflammatory bowel disease. Accordingly,
PPARc deletion in macrophages exaggerated clinical and
pathological outcomes in a mouse model [55]. Global gene
expression analysis of PPARc-deficient colonic macrophages
showed altered expression of 124 genes compared to control
littermates. An IPA analysis of these genes showed two main
pathways compromised: (i) carbohydrate metabolism and (ii)
immunological disease suggesting that both alterations in the
metabolism and immune function of macrophages are respon-
sible for the observed disease phenotype [56].
Berthier et al. performed a large-scale interconnection anal-
ysis in human and murine lupus nephritis renal biopsies using
an algorithm called Tool for Approximate Subgraph Matching
of Large Queries Efficiently to identify related networks
affected in both species. Surprisingly, both in human and
murine samples, macrophage/DC-related genes were affected.
With this approach, the authors could identify an enhancement
of PPARc-dependent regulation in glomerular macrophages
[57]. Supporting these results, R}oszer et al. found that macro-
phage-specific deletion of PPARc in mice resulted in autoim-
mune kidney disease resembling certain aspects of human
lupus nephritis. It was proposed that the pathological autoim-
mune response was a result of impaired phagocytosis of
apoptotic cell debris throughout the body [58].
As stated above, PPARc is involved in macrophage lipid
metabolism as well [59]. One of the best-studied examples of
this effect is the PPARc response element in the promoter of the
scavenger receptor CD36, by which this gene responds to
PPARc activation [60,61]. This receptor uptakes the oxidized
low-density lipoprotein (LDL) in a cell type- and context-de-
pendent manner [46]. Oxidized LDL is formed during the early
stages of atherosclerosis, when oxidative modifications in the
components of LDL complex are initiated driving the formation
of fatty streaks in the endothelium of large arteries. This is
accompanied by continuous macrophage accumulation with
oxidized LDL uptake that serves as a crucial step in the course
of atherosclerotic lesion formation [62]. Accordingly, in a
murine model of mild and severe hypercholesterolemia the
macrophage-specific deletion of PPARc exacerbated
atherosclerosis. The anti-atherogenic effect of the receptor in
macrophages is probably attributable to its role in activating the
LXR-ABCA1/ABCG1 cholesterol efflux pathway as well as to
its inhibitory effect on CCR2, thereby presumably decreasing
monocyte recruitment to plaques [63]. Corroborating these
observations, PPARc agonist thiazolidinedione treatment alle-
viated atherosclerosis in LDL deficient murine models and
decreased the expression of inflammatory markers. Further-
more, atherosclerotic lesions were increased in size in PPARc
null bone marrow transplanted LDL-deficient mice [46,63,64].
In the same in vivo model, it has been observed that rosiglita-
zone treatment reduced cholesterol accumulation in part inde-
pendently from the LXR-regulated cholesterol efflux pathway
[65]. A transcriptome study on human stable and ruptured
atherosclerotic plaques showed that the most upregulated
pathway in ruptured plaques was the PPAR/Adipocytokine
signaling pathway, suggesting a so far unexplored contribution
of the receptor in the formation of unstable plaques [66]. It is
clear, based on the studies above, that macrophage-expressed
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PPARc has a significant impact on the pathogenesis and
progression of atherosclerosis. Nevertheless, crucial genome-
wide studies are still missing that could describe the entire
spectrum of PPARc-responsive macrophage gene networks in
the context of atherosclerosis. PPARc ChIP-seq together with
RNA-seq, and mapping of active enhancers using a combina-
tion of histone modification-specific ChIP-seq and ATAC-seq
[67] in macrophages isolated from different stages of disease
progression could identify novel PPARc targets, potentially
representing targets for pharmacological intervention as well.
In addition, inflammatory reactions can be inhibited in
numerous cell types, including endothelial cells, using PPARc
agonists [68], making PPARc an interesting target for preven-
tion and treatment of atherosclerosis.
It has been proposed that PPARc acts as an important regu-
lator in adipose tissue macrophages as well. Adipose tissue
macrophages are responsible for maintaining an anti-inflam-
matory equilibrium in adipose tissue, thereby influence meta-
bolic processes at a systemic level. It is thought that this
equilibrium becomes disturbed in obesity. It has been shown
using a combination of transcriptome analyses and immuno-
histological studies that there is an increased number of
macrophages in adipose tissue of obese individuals, correlating
with the body mass [69]. These macrophages are the primary
source of TNFa, IL-6 and iNOS expression in adipose tissue. It
is proposed that these macrophages secreting inflammatory
mediators participate actively in maintaining a chronic low-
grade inflammation in obese individuals, which will lead to
insulin resistance and type 2 diabetes mellitus [70]. Odegaard
et al. [34] found that mice lacking PPARc in their macrophages
were predisposed to diet-induced obesity and insulin resis-
tance. Moreover, macrophage PPARc has been shown to be
indispensable for the full antidiabetic effect of thiazolidine-
diones [71]. It is important to note, however, that these results
could not be confirmed using a different mouse strain and
experimental model [72].
As PPARc serves as an essential transcription factor during
adipocyte differentiation, it is an intriguing question whether
the PPARc-regulated gene networks in macrophages and adi-
pocytes share similarities. It turned out that indeed the receptor
influences overlapping pathways in macrophages and adipo-
cytes including genes regulating lipid metabolism such as
lipoprotein lipase, acetyl coenzyme A acetyltransferase and
phospholipase A [73]. At the same time, the receptor exhibits
functions, which are cell type specific and involve different
signalling pathways in each cell type (Fig. 1). To elucidate the
mechanisms responsible for the cell type-specific effects, a
genomewide study using ChIP-seq technologies has been per-
formed. Lefterova et al. [27] investigated the differences
between the PPARc-binding sites in macrophages and adipo-
cytes. According to this study, the PPARc cistrome shows cell
type specificity; however, 30% of the binding sites overlap
between macrophages and adipocytes [27]. These data also
support that tissue-specific PPARc function is modulated by
the accessibility of binding sites determined by chromatin
conformation, and concurrent binding of tissue-dependent
transcription factors (e.g. PU-1 in macrophages and C-EBP in
adipocytes).
Schneider et al. [29] recently found that PPARc is also
essential for the differentiation of foetal monocytes into alveolar
macrophages, but not for other tissue-resident macrophages.
The authors used microarray data to identify the unique tran-
scriptional signature that PPARc grant to alveolar macrophages
[29]. Lavin et al. [67] confirmed these observations by mapping
the enhancer landscapes of macrophages with different tissue
origins using a combination of RNA-seq, ChIP-seq and ATAC-
seq methods. They found that the PPARc-binding motif was
overrepresented among enhancers specific for lung macro-
phages [67].
Therefore, based on the recent advancements in our under-
standing regarding the function of the receptor in tissue
macrophages, it is clear that more genomewide transcriptome
and epigenome analyses are needed in mouse knock-out
models and in human diseases to decipher the entire com-
plexity of PPARc activity.
PPARc in dendritic cells
Dendritic cells (DCs) constitute a system of cells bridging
innate and adaptive immune responses through their ability to
orchestrate a wide range of lymphocyte responses according to
signals perceived in the periphery. In most tissues, DCs are
present in an immature state, unable to stimulate T cells, but
specialized to capture and process antigens. Various stimuli
(e.g. microbial products, lymphocyte-derived signals, endoge-
nous mediators) are capable of inducing a maturation process,
characterized by a switch from antigen sampling to antigen
presenting and lymphocyte stimulatory activity, which requires
enhanced surface expression of MHC and costimulatory sur-
face molecules (CD40, CD80, CD86). After migration to sec-
ondary lymphoid organs, activated DCs induce antigen- and
tissue-specific adaptive responses. DCs also control the nature
of T-cell response by driving the differentiation of na€ıve T cells
into different effector T-cell subsets through exhibiting distinct
secreted cytokine profiles. In addition to their role in adaptive
immunity, DCs also elicit innate immune responses by pro-
ducing cytokines involved in host defence, such as IL-12 and
interferons, and by activating NK and NKT cells [74]. In the
course of their lifecycle, DCs encounter continuously changing
microenvironments containing a diverse range of lipids.
The lipid microenvironment can influence DC phenotypes;
therefore, inducing DC elicited immune responses via
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G-protein-coupled receptors and nuclear hormone receptors.
Among the latter, PPARc is increasingly appreciated as a sen-
sor capable of translating lipid signals into gene expression
changes, thereby shaping DC function. It seems though that the
gene networks orchestrated by the receptor in macrophages
and DCs are distinct (Fig. 2).
Microarray analyses revealed that during ex vivo DC differ-
entiation from human monocytes, a group of genes involved in
lipid metabolism is upregulated. These genes encode proteins
implicated in the production, uptake, transport and solubi-
lization of cholesterol and fatty acids [75]. Several of them
produce lipid metabolites capable of activating PPARc, such as
monoamine oxidase A-produced serotonine metabolites or 15-
lipoxygenase-produced eicosanoids [52,76]. PPARc shows a
marked and rapid upregulation during this differentiation
process, as well. Thus, it seems that DC differentiation induces
a switch of PPARc signalling pathway to a state when the
receptor is, at least, ready to be activated by its intracellular
ligands or lipids of extracellular origin, such as 15d-PGJ2, LPA
or oxLDL [77–79]. Research from the last decade has shown
that activation of this signalling pathway affects both the
metabolism and immune phenotype of DCs [80].
The complexity of the downstream effects of PPARc activa-
tion has been revealed in its entirety by the global gene
expression analysis of human monocyte-derived DCs differ-
entiated in the presence of rosiglitazone for different time spans
[81]. The results derived from this analysis indicated that
PPARc does not act as a general inhibitor of DC development,
as the vast majority of genes regulated upon ex vivo DC dif-
ferentiation showed unaltered expression in the presence of
(a) (b)
Figure 2 18PPARc signalling networks in macrophages and dendritic cells. List of genes affected by PPARc published in The National
Center for Biotechnology Information in macrophages (a) and dendritic cells (b) were generated by the online access software
Genes2FANs. Next, using the same software, networks for PPARc signalling were obtained in these two different cell types [10].
Nodes which were obtained from the seed list (list of genes directly linked to PPARc based on publication data) are coloured in blue,
intermediated nodes (genes linked to the components of the seed list) with a significant z-score are coloured in orange,
intermediated nodes with nonsignificant z-score are coloured in grey (significance cutoff = 25). Already published data can be used
to generate gene lists and networks for identifying novel regulated pathways in different cell types.
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rosiglitazone. Rather, PPARc activation appears to skew DC
differentiation, creating a unique DC subset in terms of its
transcriptional profile and consequential functional properties.
Human serum enhances PPARc activity in ex vivo differentiated
DCs, suggesting that continuous low-level activation of PPARc
signalling might be an integral part of the differentiation pro-
cess in vivo. The dynamic temporal changes in PPARc-regu-
lated genes reflect the two-faced role of the receptor in immune
regulation, connecting metabolic and immune functions
(Fig. 3). After 6 h, the category of lipid and fatty acid metabo-
lism was markedly overrepresented among the genes upregu-
lated by rosiglitazone. These include genes involved in fatty
acid oxidation (e.g. ACOX1, HADHSC), phospholipid and tri-
acylglycerol synthesis (e.g. DGAT2, PPAP2B) and lipid uptake/
transport (e.g. CD36, FABP4), showing that the receptor
simultaneously regulates antagonistic metabolic processes. The
net effect of these transcriptional changes seems to be the
enhanced capacity of DCs to metabolize and redistribute lipids,
as rosiglitazone-treated DCs accumulated fewer lipid droplets.
After 24 h, among the genes regulated by rosiglitazone
immune response-related genes showed a marked enrichment.
Amid these, the CD1 group of surface protein encoding genes
showed coordinate regulation by PPARc characterized by
decreased expression of CD1a, CD1b, CD1c together with CD1e
and elevated expression of CD1d molecules [79]. These MHC
class I-likemolecules are implicated in lipid antigen presentation
to T cells. Group I CD1 molecules (CD1a, CD1b, CD1c) present
self-lipid antigens and microbial lipid antigens, whereas Group
II (CD1d) molecules primarily bind self-lipid antigens [82]. In
contrast to Group I CD1 molecules, which are recognized by
TCRs showing diverse rearrangements, CD1d proteins are able
to interact with T cells carrying invariantly rearranged TCRs, as
well. These CD1d-restricted T cells are referred to as invariant
natural killer T (iNKT) cells [83]. Enhanced expression of CD1d
in PPARc-instructed DCs endows them with the ability to
selectively induce Va24+Vb11+ iNKT cell expansion in the pres-
ence of certain lipid antigens [79]. iNKT cells have cytolytic
activity and rapidly induce the expression of IL-4, IL-13 and IFNc
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Figure 3 Network visualization of Gene Ontology Enrichment Analysis of human monocyte-derived dendritic cells differentiated in
the presence of rosiglitazone using BiNGO Cytoscape plugin [89]. Nodes represent enriched Gene Ontology terms, and node
colours represent corresponding Benjamini-Hochberg FDR corrected enrichment P values. Analysis is based on the microarray
experiment of Szatmari et al. (GEO ID: GSE8658) [81].
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after TCR stimulation, which, in turn, can activate NK cells, T
cells, B cells, macrophages and recruit DCs. The rapid activation
of iNKT cells potentially renders them powerful effectors of the
early phases of immune response.
The regulation of CD1d expression and subsequent iNKT cell
expansion by PPARc takes at least 24 h to develop that
suggested an indirect mechanism instead of direct transcrip-
tional activity of the receptor. By studying the global gene
expression profile of PPARc-activated human DCs, Szatmari
et al. found that activation of PPARc induces the retinoid
pathway responsible for controlling CD1d expression. Specifi-
cally, activated PPARc induces the expression of retinal- and
retinol-metabolizing enzymes leading to increased intracellular
generation of all-trans retinoic acid (ATRA) from retinol. ATRA
activates retinoic acid receptor-a (RARa), which, in turn,
induces CD1d transcription. ATRA-induced CD1d expression
confers the ability to selectively activate iNKT cells [84].
Microarray analyses of DCs treated with the combination of
rosiglitazone and an RARa antagonist made it possible to
determinewhatportion ofPPARc-regulatedgenes are controlled
indirectly via induced retinoid synthesis and subsequent RAR
activation. Unexpectedly, this analysis revealed that approxi-
mately 30% of PPARc ligand-responsive genes in DCs are regu-
lated through the induction of the retinoid pathway [84].
Activation of PPARc in human monocyte-derived DCs also
upregulated several genes that are normally downregulated
during DC differentiation (e.g. PDK4, CD1d, TLR4, CD36, leu-
kotriene B4 receptor, transcription factor ATF3), possibly con-
tributing to the development of a distinct PPARc-instructed DC
phenotype. At the same time, 667% of genes, which were
negatively regulated by rosiglitazone treatment were induced
during DC differentiation (group I CD1s, IL1R1, IL1R2, IRF4,
CD80, DCNP1), showing that the receptor inhibits certain
aspects of the differentiation process [81].
The microarray data of human ex vivo differentiated DCs,
described above, were compared recently to the trascriptomic
profiles of CD1a+MHCII+ lung myeloid DCs from smokers with
and without emphysema. Interestingly, this analysis revealed
an opposite gene expression pattern between the two data sets,
namely, genes induced by PPARc activation were decreased in
emphysema, and genes downregulated by PPARc activation
showed upregulation in emphysema. These findings suggested
an important negative regulatory role for the receptor in mye-
loid DCs in chronic lung inflammation. Confirming the geno-
mewide analyses, mice exposed to smoke showed decreased
expression of PPARc in their lung DCs. Furthermore, animals
with PPARc-deficient DCs developed spontaneous emphysema
revealing a crucial role for the receptor expressed by myeloid
cells in controlling the inflammatory response in the lung trig-
gered by cigarette smoke [85].
Box 116 Glossary of large-scale data acquisition technologies
Microarray
Based on hybridization of complementary nucleic acid
strands and one of the most widely used technology to
identify dynamic transcriptomes in normal and disease
states, gives poor performance in quantification of less
abundant transcripts.
Next-generation sequencing (NGS)
Uses massive parallel analysis of individually amplified
DNA fragments and produces short (35–400 bp) but
tremendous amount (up to 107) of sequence reads.
Targets of NGS analysis can be not only the genomic, but
methylated DNA, expressed mRNA (RNA-seq), DNase I
hypersensitive DNA regions, regions bound by a specific
transcription factor (ChIP-seq), or open chromatin regions
(ATAC-seq).
ChIP-seq
Based on chromatin immunoprecipitation, where a protein
specific antibody is used to purify DNA fragments that are
associated with the protein of interest, for instance PPARc
or its heterodimeric partner RXR. ChIP-seq has already
revolutionized our understanding of how transcription
factor binding and epigenetic modifications control gene
expression on a system level.
RNA-seq
Through deep-sequencing of cDNA, this approach allows
us to determine the expression levels of whole transcripts
and isoforms at a given physiological or developmental
stage. These transcripts include the following: noncoding
RNAs, small RNAs and mRNA.
ATAC-seq
The assay for transposase-accessible chromatin using
sequencing (ATAC-seq) is based on direct transposition of
sequencing adaptors into native chromatin. This way,
ATAC-seq identifies open chromatin regions throughout
the genome and revealing the interplay between genomic
locations of open chromatin, DNA-binding proteins, indi-
vidual nucleosomes and chromatin compaction at nucleo-
tide resolution.
3D imaging
Fluorescent microscopy or contrast imagining technics
sections can be processed by computational specific soft-
ware’s. The data obtained from this approach can be used to
draw models from cells to whole organism behaviour after
a stimulus or during developmental stage.
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PPARc forms a permissive heterodimer with RXR that can be
potentially activated both by PPARc and RXR ligands. By com-
paring the transcriptome of humanmonocyte-derived DCs after
specific PPARc andRXR activation, Szeles et al. found that only a
subset of PPARc target genes possesses dual ligand regulation.
The majority of these genes were regulated to a lesser extent by
RXR activation; thus, the permissiveness of PPARc/RXR het-
erodimer seems to be only partial in DCs [86].
In conclusion, global gene expression profiling made it pos-
sible to decipher PPARc-regulated transcriptional changes
throughout the genome and identify new lipid-responsive
pathways that shape the functional properties of DCs. It is
important to note though that studies on PPARc-regulated
transcriptome were all carried out using ex vivo differentiated
DCs. Thus, it would be crucial to extend studies on the cistrome
and transcriptome of the receptor to DCs of in vivo origin in the
steady state of the immune system and also in the context of
different disease challenges.
Concluding remarks
In the last four decades, many molecular components of the cell
have been identified in the hope that it helps to understand
how individual cells work and in particular, how various cells
work as a well-orchestrated system in our body. In particular in
the recent years, microarray, next-generation sequencing tech-
nologies, and more recently mass spectrometry, have made
possible the generation of comprehensive data sets from a
variety of biological systems.
In this review, we have attempted to demonstarte how high-
throughput methods changed our view on the biological func-
tion of PPARc. We emphasized that integrating data from high-
throughput data collection methods (e.g. microarray, RNA-seq,
ChIP-seq, mass spectrometry) is essential to develop a deeper
understanding of how the immune system operates at various
scales and what functions its individual components execute.
Our summary of the multiple functions of PPARc in macro-
phages and dendritic cells clearly demonstrate the existence of
crosstalk across multiple pathways, feed-forward and feed-
back loops present in the PPARc network. Thus, representation
of the PPAR signalling pathway as linear cascades funnelling
signals from cell membrane to the nucleus is clearly an over-
simplification of reality.
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